Skip to main content

During the third quarter of 2026, the U.S. Food and Drug Administration approved cancer treatments that expanded the options for patients with skin, genitourinary, breast, lung, gastroesophageal, pancreatic, and bile duct cancers, as well as several hematologic malignancies and solid tumors with certain features. Learn about each new approval and how it fits into the therapeutic landscape.

The post FDA Approvals in Oncology: July-September 2026 appeared first on American Association for Cancer Research (AACR).

Source: Oncology

Read More